OPKO Health Inc.
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
OPK | TA
Overview
Corporate Details
- ISIN(s):
- US68375N1037
- LEI:
- Country:
- Israel
- Address:
- 4400 Biscayne Blvd., 33137 Miami
- Website:
- https://www.opko.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
OPKO Health, Inc. is a diversified and fully-integrated healthcare company operating in the diagnostics and pharmaceuticals sectors. Its diagnostics division features BioReference Laboratories, one of the largest full-service clinical reference laboratories in the U.S. The pharmaceuticals division focuses on discovering, developing, and commercializing novel therapies for serious diseases. Key marketed products include NGENLA™, a next-generation human growth hormone therapy for pediatric patients, and RAYALDEE®. The company's research pipeline is centered on advancing multispecific therapies for conditions like cancer and infectious diseases, supported by strategic partnerships with leading pharmaceutical and scientific organizations such as Pfizer and Merck.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-02 00:00 |
Director's Dealing
Immediate Report
|
English | 83.2 KB | ||
| 2025-11-02 00:00 |
Foreign Filer Report
Immediate Report
|
English | 36.3 KB | ||
| 2025-10-30 00:25 |
Quarterly Report
Report of Periodic or Interim Report
|
English | 1.4 MB | ||
| 2025-10-30 00:25 |
Foreign Filer Report
Report of Periodic or Interim Report
|
English | 36.6 KB | ||
| 2025-10-30 00:23 |
Earnings Release
Immediate Report
|
English | 1.4 MB | ||
| 2025-10-30 00:23 |
Foreign Filer Report
Immediate Report
|
English | 36.5 KB | ||
| 2025-10-29 15:17 |
M&A Activity
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regene…
|
English | 289.1 KB | ||
| 2025-10-29 15:17 |
Foreign Filer Report
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regene…
|
English | 36.5 KB | ||
| 2025-10-28 15:09 |
Regulatory News Service
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treat…
|
English | 302.7 KB | ||
| 2025-10-28 15:09 |
Foreign Filer Report
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treat…
|
English | 36.4 KB | ||
| 2025-10-23 11:02 |
Report Publication Announcement
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
|
English | 179.7 KB | ||
| 2025-10-23 11:02 |
Foreign Filer Report
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
|
English | 36.4 KB | ||
| 2025-10-02 23:09 |
Major Shareholding Notification
Immediate Report
|
English | 514.3 KB | ||
| 2025-10-02 23:09 |
Foreign Filer Report
Immediate Report
|
English | 36.3 KB | ||
| 2025-09-16 11:31 |
M&A Activity
Labcorp completes acquisition of select assets of BioReference.
|
English | 117.0 KB |
Automate Your Workflow. Get a real-time feed of all OPKO Health Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OPKO Health Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OPKO Health Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
